Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

2.0 / 5 stars · 47/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

EMERGENT BIOSOLUTIONS INC. (EBS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$9.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-27

  • EMERGENT BIOSOLUTIONS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$9.40M.
  • EMERGENT BIOSOLUTIONS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $192.70M, a 409.79% increase from fiscal 2022.
  • EMERGENT BIOSOLUTIONS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $37.80M.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed
2025-12-31-$9.40M
10-K · filed 2026-02-27
2023-12-31$192.70M
10-K · filed 2024-03-08
2022-12-31$37.80M
10-K/A · filed 2023-12-11
$43.00M
10-K · filed 2023-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45